Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical insulin eye drops versus autologous serum for persistent corneal epithelial defects
2022-003589-19Phase 3Active
- Sponsor
- Pedro Arriola-Villalobos
- Start
- Feb 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of human insulin in corneal persistent epithelial defect (PED) (2 arms), sponsored by Pedro Arriola-Villalobos. Primary endpoint: No epithelial defect. Started Feb 2023; status: active.
02
Drugs
human insulin
03
Conditions
corneal persistent epithelial defect (PED)
Beyond the preview
Go deeper on 2022-003589-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-003589-19.